References
- Agarwal C, Singh RP, Dhanalakshmi S, et al. (2003). Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 22:8271–82
- Ahmad A, Wang Z, Ali R, . (2012). Cell cycle regulatory proteins in breast cancer: Molecular determinants of drug resistance and targets for anticancer therapies. In: Rebecca A, ed. Targeting New Pathways and Cell Death in Breast Cancer. InTech, 113–30. Available from: http://cdn.intechopen.com/pdfs-wm/29441.pdf [last accessed 13 Oct 2014]
- Antonsson B, Martinou J. (2000). The Bcl-2 protein family. Exp Cell Res 256:50–7
- Bresalier RS, Sandler RS, Quan H, et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–102
- Chansriniyom C, Ruangrungsi N, Lipipun V, et al. (2009). Isolation of acridone alkaloids and N-[(4-monoterpenyloxy)phenylethyl]-substituted sulfur-containing propanamide derivatives from Glycosmis parva and their anti-herpes simplex virus activity. Chem Pharm Bull (Tokyo) 57:1246–50
- De Gramont A, Figer A, Seymour M, et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–47
- Debatin KM. (2004). Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immun 53:153–9
- Fisher DE. (1994). Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539–42
- Greger H, Zechner G, Hofer O, et al. (1993). Sulphur-containing amides from Glycosmis species with different antifungal activity. Phytochemistry 34:175–9
- Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: The next generation. Cell 144:646–74
- Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:69–90
- Koehne CH, Dubois RN. (2004). COX-2 inhibition and colorectal cancer. Semin Oncol 31:12–21
- Lievre A, Bachet JB, Le Corre D, et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–5
- Mans DR, Da Rocha AB, Schwartsmann G. (2000). Anti-cancer drug discovery and development in Brazil: Targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist 5:185–98
- Markowitz SD, Bertagnolli MM. (2009). Molecular basis of colorectal cancer. N Engl J Med 361:2449–60
- Park MT, Lee SJ. (2003). Cell cycle and cancer. J Biochem Mol Biol 36:60–5
- Rethy B, Zupko I, Minorics R, et al. (2007). Investigation of cytotoxic activity on human cancer cell lines of arborinine and furanoacridones isolated from Ruta graveolens. Planta Med 73:41–8
- Siripong P, Hahnvajanawong C, Yahuafai J, et al. (2009). Induction of apoptosis by rhinacanthone isolated from Rhinacanthus nasutus roots in human cervical carcinoma cells. Biol Pharm Bull 32:1251–60
- Siripong P, Yahuafai J, Shimizu K, et al. (2006). Antitumor activity of liposomal naphthoquinone esters isolated from Thai medicinal plant: Rhinacanthus nasutus KURZ. Biol Pharm Bull 29:2279–83
- Tol J, Koopman M, Cats A, et al. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–72
- Wang D, Dubois RN. (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29:781–8